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Abstract
Background: To evaluate the expression and differential diagnostic significance of CK19, TG, Ki67 and galectin-3 in
papillary thyroid carcinoma (PTC) (metastatic and non metastatic), follicular adenoma and nodular goiter in patients
from the northeastern part of China.
Methods: 441 PTC specimens and 151 other benign thyroid specimens (97 cases of nodular goiter, 54 cases of
nonmalignant follicular adenoma) were collected. Immunohistochemistry for CK19, TG, Ki67 and galectin-3 was
performed.
Results: CK19, TG, Ki67 and galectin-3 expression was 96.37% (425/441), 82.77% (365/441), and 40.59% (179/441),
96.82% (427/441), respectively, for the PTC group and the expression of these markers in the benign thyroid lesions
group was 25.83% (39/151), 79.47% (120/151), and 37.09% (56/151), 50.99% (77/151), respectively. The expression of
CK19 and galectin-3 in PTC was much higher than that in the nonmalignant group (p < 0.05). However, the
expression of TG, Ki67 did not differ among these two groups (p > 0.05). The diagnostic efficiency of CK19 and
galectin-3 for PTC was 96.37% (537/592) and 84.63% (501/592). CK19 and galectin-3 expression rate in PTC was
higher than that in benign disease cases.
Conclusions: The diagnostic efficiency of CK19 for PTC was slightly better than galectin-3. The utilization of these
markers combined with morphologic evaluation may be helpful in the differential diagnosis of papillary thyroid
carcinoma in the northeastern region of China.
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Background
Thyroid cancer is the most common endocrine malig-
nant tumor and encompass the most common well-dif-
ferentiated papillary carcinoma (80% of all thyroid
cancers) and follicular carcinoma (15%), as well as
poorly differentiated carcinoma (< 1%) and anaplastic
carcinoma (< 2%) [1]. PTC is the most common form of
thyroid cancer, however, it is often difficult to differenti-
ate PTC from benign papillary hyperplasia of the thyroid
gland based on their morphology [2]. Some proteins’
alteration was found in thyroid cancer, such as CK19,
TG, Ki67, Calcitonin, TTF-1, BRAF, RET, HBME-1,
SERPINA1, TfR1/CD71, FHL1 and galectin-3 [3-12].
In the recent years, a large number of molecular
alterations in thyroid cancer have been used in the dis-
tinction of malignant from benign thyroid lesions. These
biomarkers, such as CK19, TG, Ki67, Calcitonin, TTF-1,
BRAF, RET, HBME-1, and galectin-3, have been trans-
lated into clinical practice which offered significant
improvement in the preoperative diagnosis of thyroid
cancer [3-6,8,11,12]. Molecular markers used in the dis-
tinction of thyroid cancer from benign thyroid lesions in
the First affiliated hospital of China Medical University
between 2008-2011 were showed in table 1. Among
these markers, galectin-3, TG, Ki67 and cytokeratin-19
(CK-19) have been most frequently used in thyroid
pathology [13-16]. In this study, we assessed four
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galectin-3, and evaluated their diagnostic significance for
papillary thyroid carcinoma in the northeastern region
of China.
Materials and methods
A total of 592 thyroid samples from the northeastern
part of China collected by the Department of pathology
in First affiliated hospital of China Medical University
between 2008 and 2011 were used in this study. There
were 441 cases in the PTC group, which included 110
men and 331 women (1:3.01), with an average age of 56
years (range 13-89 years). The diagnosis of papillary car-
cinomas were based on characteristic cytologic features,
which includes nuclear irregularity (nuclear grooves,
clearing, and increased size) and pseudoinclusions [12].
The nonmalignant group contained 151 cases (97 cases
of nodular goiter, 54 cases of nonmalignant follicular
adenoma) which included 38 men and 113 women
(1:2.97), with an average age of 45 years (range 25-68
years). All resected specimens were fixed in 10% neutral
buffered formalin (pH 7.4), embedded in paraffin, cut
into 5-μm sections, and stained with hematoxylin and
eosin (H&E). Informed consent was obtained from all
patients that donated their specimens, and all experi-
ments were approved by the hospital’s ethics committee.
Reagents
The antibodies included: CK19 (mouse monoclonal anti-
human antibody sc-53258; 1:50; Santa cruz biotechnol-
ogy, CA, USA); TG (mouse monoclonal antibody sc-
53543; 1:100; Santa cruz biotechnology, CA, USA); Ki67
(mouse monoclonal antibody sc-23900; 1:100; Santa
cruz biotechnology, CA, USA) and galectin-3 (mouse
monoclonal anti-human anti-body clone: 9C4; 1:50; Beij-
ing Zhong Shan Biotechnology, Beijing, China).
Immunohistochemistry
Immunostaining has been performed by using monoclonal
antibodies for CK19, TG, Ki67 and galectin-3. After depar-
afinisation the sections were rehydrated. Endogenous
peroxidase activity was blocked by 3% hydrogen peroxide.
Antigen retrieval was performed in a microwave oven for
15 min in 10 nM citrate buffer pH 6.0 for all primary anti-
bodies. The sections were incubated at room temperature
for 2 h with primary monoclonal antibodies. After washing
in phosphate-buffered saline, the tissues were incubated
with a biotin-conjugated secondary antibody for 1 h at
room temperature. The reactions became visible after
immersion of diaminobenzidine tetrahydrochloride (DAB).
Immunohistochemical Evaluation
The cells were regarded as positive for these markers
when immunoreactivity was clearly observed in their
cell membrane and/or cytoplasm. For each antibody,
immunoreactivity (no staining or weak staining less than
10% of the cells) was scored as negative and other
immunoreactivity was scored as positive.
Statistical Analysis
Statistical analysis was performed using SPSS V.11.5.
The X
2 test and Fisher exact test were used for compar-
ison of the immunohistochemistry results between the
PTC and nonmalignant groups. Sensitivity (true posi-
tive/true positive + false negative), specificity (true nega-
t i v e / t r u en e g a t i v e+f a l s ep o s i t i v e ) ,F a l s en e g a t i v er a t e
(1-Sensitivity), False positive rate (1-specificity), and
diagnostic accuracy (true positive + true negative/all
positives + all negatives) of each marker were assessed
in papillary thyroid carcinomas.
Results
Immunohistochemistry results
In order to evaluate the diagnostic significance of CK19,
TG, Ki67 and galectin-3 expression in the distinction of
PTC from benign thyroid lesions, we detected these
markers expression by using immunohistochemistry.
The result of immunohistochemistry was seen in Figure
1. As showed in Table 2, CK19, TG, Ki67 and galectin-3
expression was 96.37% (425/441), 82.77% (365/441), and
40.59% (179/441), 96.82% (427/441), respectively, for the
PTC group and the expression of these markers in the
benign thyroid lesions group was 25.83% (39/151),
79.47% (120/151), and 37.09% (56/151), 50.99% (77/
151), respectively. The expression of CK19 and galectin-
3 in PTC was much higher than that in the nonmalig-
nant group (p < 0.05). However, the expression of TG,
Ki67 did not differ among these two groups (p > 0.05).
Then we analyzed CK19 and Galectin-3 expression in
PTC with or without lymphatic metastasis and different
benign thyroid lesions. As showed in Table 3 and Figure
2, Galectin-3 positive rate in these four groups was
52.58% (nodular goiter), 48.15% (follicular adenoma),
97.17% (papillary thyroid carcinoma without lymphatic
metastasis) and 96.37% (papillary thyroid carcinoma
Table 1 Molecular markers used in the distinction of
malignant from benign thyroid lesions
Description Gene symbol
thyroid transcription factor-1 TTF-1
GALECTIN 3 GAL3
Calcitonin CALCA
HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34 CD34
keratin, type I cytoskeletal 19 CK19
Thyroglobulin Tg
KI67 Antigen MKI67
TUMOR PROTEIN p53 P53
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rate in these four groups was 26.80% (nodular goiter),
24.08% (follicular adenoma), 99.20% (papillary thyroid
carcinoma without lymphatic metastasis) and 92.74%
(papillary thyroid carcinoma with lymphatic metastasis),
respectively. CK19 and Galectin-3 expression did not
differ among nodular goiter and follicular adenoma or
PTC with lymphatic metastasis and PTC without lym-
phatic metastasis. There was significant difference in
CK19 and Galectin-3 expression between nodular goiter
(or follicular adenoma) and PTC with lymphatic metas-
tasis (or PTC without lymphatic metastasis), P < 0.05.
At last, diagnostics performance of CK19 in the dis-
tinction of PTC from benign thyroid lesions was com-
pared with that of Galectin-3. As showed in Table 4,
Diagnostic efficiency of CK19 (90.71%) was slightly
higher than that of Galectin-3(84.63%) and the specifi-
city and false positive rate (misdiagnosis rate) of CK19
was better than Galectin-3.
Discussion
Papillary carcinoma is the most common malignancy ori-
ginating from the thyroid. Conventionally, discrimination
between benign and malignant thyroid nodules is
attempted by fine needle aspiration biopsy (FNAB) fol-
lowed by cytological assessment [1]. Despite many
advances in the diagnosis and treatment of thyroid
nodules and thyroid cancer, these methods have a well
known low specificity [3,4]. The searching of the reliable
and repeatable immunohistochemical markers in the dis-
tinction between benign thyroid nodules and papillary
thyroid carcinoma is urgent. To date, many studies have
tried to classify the different biomarkers of thyroid carci-
noma on the basis of their gene expression profiles. Some
proteins’ alteration was found in thyroid cancer, such as
CK19, TG, Ki67, Calcitonin, TTF-1, BRAF, RET, HBME-
1, SERPINA1, TfR1/CD71, FHL1 and galectin-3 [3-12].
Some of these proteins could be applicable to differenti-
ate thyroid cancer from benign thyroid lesions in clinical
practice. Molecular markers used in the distinction of
Figure 1 CK19, TG, Ki67 and galectin-3 immunoreactivity in PTC and nonmalignant thyroid lesion. A-E: HE, CK19, TG, Ki67 and galectin-3
staining in PTC; a-e: HE, CK19, TG, Ki67 and galectin-3 staining in nonmalignant thyroid lesion. Scale bar: 50 μm.
Table 2 Immunohistochemistry results in papillary
thyroid carcinoma (PTC) and other nonmalignant thyroid
lesions
Nonmalignant lesions
N = 151
PTC
N = 441
X
2 P
CK19 + 39(25.83) 425(96.37) 326.17 6.56E-73
- 112(74.17) 16(3.63)
Tg + 120(79.47) 365(82.77) 0.62 0.43
- 31(20.53) 76(17.23)
Ki67 + 56(37.09) 179(40.59) 0.44 0.51
- 95(62.91) 262(59.41)
Galectin + 77(50.99) 427(96.82) 183.10 1.02 E-41
- 74(49.01) 14(3.18)
Table 3 Immunohistochemistry results of CK19 and
Galectin-3 in papillary thyroid carcinoma (PTC) with or
without lymphatic metastasis and other nonmalignant
thyroid lesions
nodular
goiter
n=9 7
Follicular
adenoma
N=5 4
PTC
1
N=
248
PTC
2
N=
193
CK19 + Female 21(21.65) 10(18.52) 202
(81.45)
121
(62.69)
Male 5(5.15) 3(5.56) 44
(17.75)
58
(30.05)
- Female 52(53.61) 30(55.56) 0(0.00) 8(4.15)
Male 19(19.59) 11(20.36) 2(0.80) 6(3.11)
Galectin + Female 37(38.15) 19(35.19) 196
(79.03)
122
(63.21)
Male 14(14.43) 7(12.96) 45
(18.14)
64
(33.16)
- Female 36(37.11) 21(38.89) 6(2.43) 7(3.63)
Male 10(10.31) 7(12.96) 1(0.40) 0(0.00)
PTC
1: papillary thyroid carcinoma (PTC) without lymphatic metastasis
PTC
2: papillary thyroid carcinoma (PTC) with lymphatic metastasis
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affiliated hospital of China Medical University between
2008-2011 were showed in table 1. In this study, we
assessed four immunohistochemical markers, CK19, TG,
Ki67 and galectin-3, and evaluated their diagnostic signif-
icance for papillary thyroid carcinoma in the northeast-
ern region of China.
Ki-67
Cell proliferative activity is one of the important factors
for assessing the biological behavior of carcinoma. At
present, the most useful marker to evaluate cell prolif-
erative activity is Ki-67, which is expressed in all cells
except those in the G0 phase [17]. Ki-67 has potential
applications in differential diagnosis between malignant
and benign lesions in human neoplasms. In thyroid neo-
plasms, Ki-67 expression has been investigated by sev-
eral groups, but it has shown conflicting. Although
some of the articles support strong expression in the
malignant group [18]. Another support that there is no
significant difference in the Ki-67 expression between
thyroid carcinoma and adenoma [19]. In this study we
found Ki-67 was expressed in 37.09% benign thyroid
lesions (nodular goiter or follicular adenoma) and
40.59% PTC cases and the difference of positive rate
between these two groups had no statistical significance.
The results suggest Ki-67 is not a suitable biomarker
used in the distinction of PTC from benign thyroid
lesions in the northeastern region of China.
TG
Thyroglobulin (Tg) is exclusively produced in thyroid
follicular cells or by thyroid tumors of follicular cell ori-
gin. Measurement of the serum Tg level is used to
monitor patients for residual or recurrent thyroid cancer
[20]. However, studies on the expression of Tg in thyr-
oid tissues were not common and Lazar et al found TG
expression was decreased in thyroid carcinomas but was
normal in the other tissues [21]. In this study we found
Tg was expressed in 79.47% benign thyroid lesions (nod-
ular goiter or follicular adenoma) and 82.77% PTC cases
and the difference of positive rate between these two
groups had no statistical significance. The results also
suggest Tg is not a suitable biomarker used in the dis-
tinction of PTC from benign thyroid lesions in the
northeastern region of China.
In this study, galectin-3 and CK19 protein were analyzed
by immunohistochemical method in the thyroid tissues
from 592 patients with histomorphological diagnosis of
nodular goiter (n = 97), follicular adenoma (n = 54), papil-
lary thyroid carcinoma without lymphatic metastasis (n =
248), and papillary thyroid carcinoma with lymphatic
metastasis (n = 93). The positive rates of Galectin-3 and
CK19 in these four groups in the northeastern region of
China were in complete agreement with Martins’ results
[22]. The difference of Galectin-3 and CK19 positive rate
between PTC and benign lesions had statistical significance
which suggests that the immunohistochemical study of
Galectin-3 and CK19 may be potential markers for PTC.
Galectin-3
Galectin-3 is a protein of the lectin family that has been
associated with neoplastic processes in various tissues
[23]. In the thyroid, expression of this protein has been
described in differentiated follicular cancer, suggesting
that the immunohistochemical study of galectin-3 may
be a potential marker of malignancy in thyroid neo-
plasms [3,12,22,24-27]. Galectin-3 positive rate in these
four groups was 52.58% (nodular goiter), 48.15% (folli-
cular adenoma), 97.17% (papillary thyroid carcinoma
without lymphatic metastasis) and 96.37% (papillary
thyroid carcinoma with lymphatic metastasis), respec-
tively. In a study by Bartolazzi et al., the sensitivity and
specificity of galectin-3 in thyroid carcinomas were 99%
and 98%, respectively [28]. In the present study, our
finding about the expression of galectin-3 in thyroid car-
cinomas was less specificity (49.01%). This may be par-
tially due to the subjective criteria used in assessing
positive expression or genetic heterogeneity of PTC in
different ethnic group.
Figure 2 CK19, TG, Ki67 and galectin-3 positive rate in nodular
goiter, follicular adenoma, papillary thyroid carcinoma without
lymphatic metastasis and papillary thyroid carcinoma with
lymphatic metastasis. PTC
1: papillary thyroid carcinoma (PTC)
without lymphatic metastasis; PTC
2: papillary thyroid carcinoma
(PTC) with lymphatic metastasis.
Table 4 Diagnostics performance of CK19 and Galectin-3
in the distinction of PTC from benign thyroid lesions
SN SP FNR FPR DAC
CK19 96.37% 74.17% 3.63% 25.83% 90.71%
Galectin-3 96.82% 49.01% 3.18% 50.99% 84.63%
SN; Sensitivity; SP: specificity; FNR: False negative rate; FPR: False positive rate;
DAC: diagnostic accuracy
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CK19 (Keratin 19) is a member of the keratin family. The
keratins are intermediate filament proteins responsible
for the structural integrity of epithelial cells. CK-19 is
strongly and diffusely expressed in papillary carcinoma,
whereas it is usually absent or focally expressed in benign
follicular nodules [29-31]. CK19 positive rate in these
four groups was 26.80% (nodular goiter), 24.08% (follicu-
lar adenoma), 99.20% (papillary thyroid carcinoma with-
out lymphatic metastasis) and 92.74% (papillary thyroid
carcinoma with lymphatic metastasis), respectively. The
role of CK-19 in the diagnosis of thyroid carcinoma is
controversial [32]. Schelfhout et al. have found CK-19
expression in all tumor cells of papillary carcinomas, but
it was absent or only focally present in follicular carcino-
mas and follicular adenomas [33]. In the current study,
although we found CK-19 expression in follicular adeno-
mas or nodular goiter but the CK-19 was the most sensi-
tive (96.37%) and specific (74.17%) marker in papillary
carcinomas. Diagnostic efficiency of CK19 (90.71%) was
slightly higher than that of Galectin-3(84.63%) and the
specificity and false positive rate (misdiagnosis rate)
CK19 was better than Galectin-3.
I nc o n c l u s i o n ,w eh a v ed e m o n s t r a t e df o u rm a r k e r s
expressed in papillary thyroid carcinomas and found Ki-
67 and Tg were not suitable biomarkers used in the dis-
tinction of PTC from benign thyroid lesions in the
northeastern region of China. The utility of galectin-3
and CK-19 may provide significant contributions in the
differential diagnosis of malignant thyroid tumors. The
utilization of these markers combined with morphologic
evaluation may be helpful in the differential diagnosis of
papillary thyroid carcinoma in the northeastern region
of China.
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